Nested Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NST-628, a Novel Pan-RAF/...
Company expects to initiate dosing in the Phase 1 study of NST-628 in patients with advanced solid tumors harboring genetic alterations in the MAPK pathway in first half of 2024 CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ -- Nested Therapeutics …